These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28778464)

  • 1. A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.
    Haass-Koffler CL; Goodyear K; Long VM; Tran HH; Loche A; Cacciaglia R; Swift RM; Leggio L
    Eur J Pharm Sci; 2017 Nov; 109():78-85. PubMed ID: 28778464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters.
    Haass-Koffler CL; Goodyear K; Long VM; Tran HH; Loche A; Cacciaglia R; Swift RM; Leggio L
    Data Brief; 2017 Dec; 15():407-413. PubMed ID: 29214202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans.
    Haass-Koffler CL; Goodyear K; Loche A; Long VM; Lobina C; Tran HH; Cacciaglia R; Swift RM; Colombo G; Leggio L
    J Psychopharmacol; 2018 Feb; 32(2):163-173. PubMed ID: 29361897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.
    Malloy J; Zhuang D; Kim T; Inskeep P; Kim D; Taylor K
    Diabetes Obes Metab; 2018 Aug; 20(8):1878-1884. PubMed ID: 29577550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
    Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
    Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.
    Gow JM; Tsuji WH; Williams GJ; Mytych D; Sciberras D; Searle SL; Mant T; Gibbs JP
    Arthritis Res Ther; 2015 Oct; 17():282. PubMed ID: 26449617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.
    Xiao F; Zhang F; Zhang LL; Wei W
    Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
    Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Yogaratnam J
    Adv Ther; 2019 Sep; 36(9):2450-2462. PubMed ID: 31267367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods.
    Sturm S; Delporte ML; Hadi S; Schobel S; Lindemann L; Weikert R; Jaeschke G; Derks M; Palermo G
    Br J Clin Pharmacol; 2018 Mar; 84(3):445-455. PubMed ID: 29096426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects.
    Royalty JE; Konradsen G; Eskerod O; Wulff BS; Hansen BS
    J Clin Pharmacol; 2014 Apr; 54(4):394-404. PubMed ID: 24166760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAGE-217, A Novel GABA
    Hoffmann E; Nomikos GG; Kaul I; Raines S; Wald J; Bullock A; Sankoh AJ; Doherty J; Kanes SJ; Colquhoun H
    Clin Pharmacokinet; 2020 Jan; 59(1):111-120. PubMed ID: 31338688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.